Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

KLRS Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Kalaris Therapeutics IncNASDAQ: KLRS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization remains negative

Q1 FY2026 depreciation & amortization was $10K, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $20K.

Context

  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near $10K or moves back toward the trailing-twelve-month quarterly average of $5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10K+0.0% QoQ
Last fiscal yearDec 2025
$13K— YoY
LTMMar 2026
$20K— YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
13K USD
Year-over-year change
—
4-year CAGR
-67.2%

Depreciation & Amortization vs competitors

How KLRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
KLRS Competitors
Depreciation & Amortization for KLRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$6.7M USD-8.9%-4.0%6.7%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M USD-3.9%+6.3%364.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$2.64M USD+6.6%+30.9%—
IMAImageneBio IncLTM Mar 2026$822K USD+129.6%+11.2%—
CNTBConnect Biopharma Holdings LimitedFY2025$704K USD+6.7%-11.9%1100.0%
IFRXInflaRx N.V.LTM Mar 2026€392.86K EUR-17.3%-11.1%1339.4%
OVIDOvid Therapeutics Inc.LTM Mar 2026$167K USD-73.0%-39.9%2.3%
CNTXContext Therapeutics Inc.LTM Mar 2026$48.3K USD+290.5%+20.6%—
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
Peer median (excluding KLRS) —+1.3%+1.1%364.3%

Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.12M00013K
Gross Profit(1.12M)000(13K)
Gross Margin—————
Research & Development119.62M11.76M11.71M12.34M30.75M
Selling, General & Admin49.08M2.24M1.76M42.92M15.39M
Operating Expenses168.7M14.01M13.46M55.26M46.14M
Depreciation & Amortization1.12M00013K
EBITDA(169.84M)(15.25M)(14.01M)(58.77M)(41.98M)
EBITDA Margin—————
Operating Income(169.82M)(14.01M)(13.46M)(55.26M)(46.15M)
Operating Margin—————
Interest Income1.32M005.49M0
Interest Expense0235K687K01.44M
Other Income / Expenses(1.14M)(1.48M)(1.24M)(3.51M)2.71M
Income Before Tax(170.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Pre-Tax Margin—————
Income Tax Expense1.01M0000
Net Income(171.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Net Margin—————
EPS (Basic)(63.00)(50.62)(42.09)(11.73)(2.85)
EPS (Diluted)(63.00)(50.62)(42.09)(11.73)(2.85)
Weighted Avg Shares2.73M3.33M4.52M5.01M15.27M
Weighted Avg Shares (Diluted)2.73M3.33M4.52M5.01M15.27M

Kalaris Therapeutics Inc

NASDAQ:KLRS

Intrinsic Alpha fair value

Locked

Current Price

$2.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.